Upcoming event

Tags

5α-Reductase inhibitors, Aanticoagulants, Actigraphy, Adenotonsillectomy, Adolescent, Antegrade ejaculation, Antidiuretic, Antimuscarinics, Apnea, Aquablation, Arousal, Avanafil, Benign Prostatic Diseases, bipolar TURO, Bladder, Bladder capacity, Bladder injury, Bladder outlet obstruction, Bladder trauma, BNC, BOO, BOOI, BPD, BPE, BPH, BPO, Chronic bacterial prostatitis, Circadian rhythms, Clinical practice guidelines, Clinical trial, Corticotropin-releasing factor, CP/CPPS, CPPS, Depression, Desmopressin, Detrusor, Detrusor hypocontractility, Detrusor overactivity, Diagnosis, Dihydrotestosterone, Drug adherence, Drug therapy, Dutasteride, EAU, Ejaculation, Ejaculation preservation, Ejaculatory dysfunction, Endoscopic surgery, Enuresis, Epidemiology, Erectile dysfunction, Fexapotide triflutate, Fibrosis, Finasteride, Fractures, Frequency volume chart, GL-XPS, GreenLight laser, Guidelines, Herbal medicines, HoLEP, Hypogonadism, Hypoxia, Impaired contractility, Incontinence, Infertility, Inflammation, Inflammatory biomarkers, Innervation, IPP, IPSS, iTIND, Laparoscopy, Laser Bipolar, Laser prostatectomy, Laser therapy, LUT, LUTS, Major cardiac adverse event, Management of Non-Neurogenic LUTS incl. BPO, Medical therapy, Melatonin, Meta analysis, Meta regression, Metabolic syndrome, Microbiome, Micturition chart, Minimally invasive surgical therapy, minimally invasive techniques, Mirabegron, Monotherapies, Multiple sclerosis, Muscarinic antagonist, Neuromodulation, nitinol, Nocturia, Nocturia Symposium, Nocturia Think Tank, Nocturnal enuresis, Nocturnal Enuresis and Alarm Treatment, Nocturnal Enuresis and Desmopressin, Nocturnal Enuresis and Quality of Life, Nocturnal polyuria, Nocturnal voiding frequency, Noninvasive, NX-1207, OAB, Obesity, Obstructive sleep apnea, Obstructive sleep apnea syndrome, Overactive bladder, Paediatric Urology, Parental punishment, Pathogenesis, Pathophysiology, Patient satisfaction, Patient-reported outcome, Permixon, Pharmacology, Phenotypically directed multimodal management, Phosphodiesterase type 5 inhibitor, Phosphodiesterase type 5 inhibitors, Phytotherapy, Placebo effect, Plasmakinetic enucleation, Potential risk factors, Prospective study, Prostate, Prostate arterial embolisation, Prostate surgery, Prostate-specific antigen, Prostatectomy, Prostatic, Prostatic arterial embolization, Prostatic artery embolization, Prostatic hyperplasia, Prostatitis, PUL, QoL, Quality of life, Randomized trial, RASP, Remission, Renal function profile, Retrograde ejaculation, Robotic, Robotic surgery, Robotics, Salivary alpha-amylase, Serenoa repens, Sexual Dysfunction, Sexual dysfunctions, Sildenafil, Simple prostatectomy, Sleep quality, Sleep-disordered breathing, Sodium diuresis, Solifenacin, Stem cells, Surgery, Surgical intervention, Sympathetic nervous activity, Systematic review, Tadalafil, Tamsulosin, Telomerase, Testosterone, ThuLEP, TmLRP, Tolterodine, TUR syndrome, TURis, TURP, Ultrasonography, Underactive bladder, urethral implantable device, Urethral injury, Urethral trauma, Urinary Incontinence in Adults, Urinary nerve growth factor, Urinary sphincter, Urodynamic, Urodynamics, Urolift, Vardenafil, Voiding, Voiding diary, Voiding dysfunction, Water diuresis, α-Adrenergic blocker, α-Adrenoceptor antagonists, α-Blocker, α-blockers, α1-Blockers
Show all

The rising worldwide impact of benign prostatic hyperplasia

BJU Int., October 2020

Alpha-1 blocker use increased risk of subsequent renal cell carcinoma: A nationwide population-based study in Taiwan

PLoS ONE, November 2020

Symptoms and noninvasive test parameters that clinically differentiate detrusor underactivity from bladder outlet obstruction without a pressure‐flow‐based diagnosis in men with lower urinary tract symptoms

Neurourol Urodyn., October 2020

Relief of Lower Urinary Tract Symptoms after MRI-Guided Transurethral Ultrasound Ablation (TULSA) for localized prostate cancer: Subgroup analyses in patients with concurrent cancer and Benign Prostatic Hyperplasia

Journal of Endourology, September 2020

Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS)

Journal of Urology, June 2020

Diagnostic assessment of lower urinary tract symptoms in men considering prostate surgery: A noninferiority randomised controlled trial of urodynamics in 26 hospitals

European Urology, June 2020

National trends in the use of PSA, urinalysis, and digital rectal exam for evaluation of lower urinary tract symptoms in men

World Journal of Urology, May 2020

Relief of lower urinary tract symptoms after MRI-Guided Transurethral Ultrasound Ablation (TULSA) for localized prostate cancer: subgroup analyses in patients with concurrent cancer and benign prostatic hyperplasia

Journal of Endourology, September 2020

Impact on sexual function of endoscopic enucleation versus transurethral resection of the prostate for lower urinary tract symptoms due to benign prostatic hyperplasia: A systematic review and meta‑analysis

Highly biased and misleading: Information on surgical treatment of benign prostatic hyperplasia on YouTube

Assessment of bladder outlet obstruction in men: A new diagnostic model based on non-invasive urodynamic parameters

Efficacy and safety of combination treatment with tadalafil and mirabegron for persistent storage symptoms despite tadalafil treatment in patients with benign prostatic hyperplasia

Next